Signet Therapeutics Wins 2025 Global Recognition Award for Pioneering 'Organoid + AI' Platform and First-in-Class Gastric Cancer Drug SIGX1094

Recently, Signet Therapeutics has been honored for its groundbreaking innovations in the field of targeted cancer therapy.2025 Global Recognition Award (GRA). This award aims toRecognizing Companies with Outstanding Innovation Achievements Worldwide`, with past winners including Tesla, Moderna, SpaceX, OpenAI, and Nvidia, among other internationally renowned companies.`

The jury, based on strict selection criteria including industry recognition, innovation, leadership, and other multidimensional indicators, ultimately awarded this honor to Signet Therapeutics.The jury particularly commended SIGNET for its outstanding performance in the following three aspects.：

SIGNET's organoid+AI technology platform precisely simulates patient tumor characteristics through 3D organoid models, and accelerates target discovery and drug screening by integrating AI technology. In less than four years, the platform has developed SIGX1094, the world’s first drug based on this technology, which has now entered Phase I clinical trials and received Orphan Drug Designation and Fast Track Designation from the U.S. FDA.

Core Pipeline SIGX1094 Poised to Become the World's First Targeted Drug for Diffuse Gastric Cancer (DGC). This highly aggressive disease with limited existing treatment options, and the successful development of SIGX1094 will fill the gap in targeted therapies for this cancer.

SIGNET's organoid technology platform not only accelerates the development of SIGX1094 but also offers new possibilities for the research and development of other novel drugs. The judging panel believes that SIGNET's organoid platform has the potential to drive global advancements in new drug discovery.

GRA is an international award aimed at recognizing companies that have achieved卓越成就 in various industries worldwide, with extensive international influence. All nominations must undergo an initial screening based on eligibility criteria, including industry recognition, innovation, leadership, service, sustainability, and social responsibility. This screening is conducted by a jury composed of industry experts and thought leaders. The shortlisted nominations will then be further screened using the Rasch model, a statistical method that converts ordinal data into interval measurements. This approach allows for a more objective comparison of applicants across different criteria. With its fair and authoritative selection mechanism, this award has attracted outstanding companies and talents from many countries around the world, establishing an excellent reputation internationally.

In the future, SIGNET will continue to focus on the research and development of innovative drugs and the development of innovative biotechnologies, accelerating the market entry of its existing pipelines to inject new momentum into the advancement of human health.

SIGNET is a global pioneer in the "organoid + AI" drug development model, recognized as a specialized and innovative enterprise in Shenzhen and certified as a National High-Tech Enterprise. The company originated on the campus of Harvard University and officially established its presence in Shenzhen by the end of 2020, having since secured nearly 220 million yuan in funding and project grants. Signet Therapeutics currently has four drug pipelines, with the first pipeline developing SIGX1094, the world’s first targeted therapy for diffuse gastric cancer. It has received IND approval from both the U.S. FDA and China's NMPA, along with Orphan Drug Designation and Fast Track Designation from the U.S. FDA, and has now entered Phase I clinical trials.

Signet is not only the phonetic translation of "Signet" but also adheres to the vision of "Full of Hope, Investigating Things to Gain Knowledge." The company leverages the critical role of organoid disease models that closely resemble patients' genomic characteristics in drug efficacy evaluation and new target discovery. By integrating AI-powered screening, synthesis, and optimization of small-molecule compounds, Signet develops first-in-class innovative targeted drugs. The company has a 1200㎡ R&D facility and a 500㎡ experimental animal housing area. SIGNET’s organoid platform not only supports its own drug pipeline but also actively empowers large pharmaceutical companies in new drug development. Collaborative partners include Shenzhen Second People's Hospital, the University of Hong Kong, the Hong Kong University of Science and Technology, Shenzhen BioRay Pharma, and Genuine Biotech, contributing to the birth of more innovative drugs.